PUBLISHER: The Business Research Company | PRODUCT CODE: 1957515
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957515
Non-viral gene delivery technologies are methods for transferring genetic material into cells without using viruses as carriers. These technologies reduce safety risks and immune responses associated with viral vectors while enabling precise and controlled gene delivery. Their primary purpose is to modify or regulate gene expression for applications such as treating genetic diseases and advancing cell-based therapies.
The main product types of non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without viral involvement. Delivery can occur through various modes, including in vitro, in vivo, and ex vivo, using technologies such as electroporation, lipid-based transfection, polymer-based transfection, physical methods (microinjection and gene gun), and nanoparticle-mediated delivery. These technologies are applied in multiple areas, including gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. Key end users include biotechnology and biopharmaceutical companies, research and academic institutes, and other organizations involved in genetic research and therapeutics.
Tariffs have impacted the non-viral gene delivery technologies market by increasing the cost of imported reagents, nanoparticles, and delivery devices, affecting both research and clinical applications. Segments like pre-formulated nanoparticles and advanced delivery devices are most affected, particularly in North America and Europe where imports constitute a significant share. While tariffs have raised operational costs and slowed adoption, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective gene delivery technologies.
The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. This non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.57 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited availability of non-viral transfection reagents, growing interest in gene therapy research, increasing use of plasmid dna and mrna delivery kits, adoption of electroporation and physical delivery techniques.
The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of advanced lipid and polymer nanoparticles, expansion of pre-formulated nanoparticle technologies, rising investment in gene editing and rnai therapeutics, increasing demand for personalized gene therapy solutions, integration of high-throughput and automated delivery platforms. Major trends in the forecast period include increasing adoption of lipid-based and polymer-based non-viral delivery systems, growth in crispr and cas9 gene editing applications, rising demand for rnai and dna vaccine delivery platforms, expansion of ex-vivo and in-vivo gene therapy research, development of cell-specific and targeted gene delivery reagents.
The surging need for personalized medicine is set to accelerate the non-viral gene delivery technologies market ahead. Personalized medicine tailors prevention, diagnosis, and therapy to an individual's distinct genetics, habits, and surroundings. This rising demand arises from progress in genomic sequencing, enabling precise diagnostics, customized treatments, and superior results suited to each patient. The heightened emphasis on personalized medicine spurs interest in non-viral gene delivery technologies, which provide secure, flexible ways to insert patient-specific therapeutic genes, avoiding viral vector hazards. For example, in February 2024, the Personalized Medicine Coalition, a US non-profit, noted that the FDA greenlit 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Hence, the escalating demand for personalized medicine is propelling the non-viral gene delivery technologies market.
Key players in the non-viral gene delivery market are advancing cutting-edge options like non-viral genetic medicine platforms to enhance gene therapy safety and performance. A non-viral genetic medicine platform introduces therapeutic genes or nucleic acids into cells sans viruses, minimizing immune responses and risks, while allowing accurate, regulated delivery for diverse conditions. For instance, in October 2023, Generation Bio Co., a US biotech firm focused on genetic medicines, unveiled immune-quiet DNA (iqDNA). This enhanced version of their closed-ended DNA (ceDNA) dodges innate immune sensing, displaying cytokine profiles and tolerance akin to modified mRNA in mice and non-human primates via lipid nanoparticle (LNP) delivery. Thanks to iqDNA's enhanced tolerability, Generation Bio is adopting it as the core DNA payload across its programs, including the flagship hemophilia A initiative.
In September 2023, SOHM Inc., a US pharmaceutical company expert in generic and private-label drug production and distribution, purchased ABBIE Inc. for an undisclosed sum. This move bolsters SOHM's expertise in non-viral gene delivery technologies, equipping it to pioneer gene-editing innovations and grow its footprint in the expanding genetic therapeutics arena. ABBIE Inc. is a US-based gene-editing platform that transports genetic payloads through non-viral vectors.
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Viral Gene Delivery Technologies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.